Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 08, 2026
TickeronGET DAILY SIGNALS
AngioDynamics (ANGO) Falls -26.8% Over 30 Days After Earnings and Leadership Update

AngioDynamics (ANGO) Falls -26.8% Over 30 Days After Earnings and Leadership Update

Key Takeaways

  • AngioDynamics shares fell roughly 26.8% over the last 30 days, from $15.22 on September 8 to about $11.14, with most of the decline arriving after the company's fiscal first-quarter report.
  • The company beat fiscal Q1 2027 revenue and adjusted EPS estimates yet still posted a GAAP loss, and the stock dropped more than 20% in the session following the results.
  • AngioDynamics announced a leadership change: Eric Honroth becomes president and chief executive officer effective November 2, 2026, succeeding retiring CEO Jim Clemmer.
  • Med Tech momentum remained strong, with revenue up 13.2% and Auryon recording its 21st consecutive quarter of double-digit growth.
  • Management reiterated full-year fiscal 2027 guidance of $336 million to $341 million in revenue and $13 million to $16 million in adjusted EBITDA.

AngioDynamics (ANGO) Business Overview and Strategic Shift

AngioDynamics, Inc. develops and sells minimally invasive, image-guided medical devices aimed at restoring blood flow, treating peripheral vascular disease, and supporting cancer therapies. The company reports results through two segments: Med Tech, which covers the Auryon atherectomy system, AngioVac and AlphaVac thrombus platforms, and the NanoKnife oncology system; and Med Device, focused on vascular access, venous products, ports, and related oncology items.

The firm has been tilting its revenue mix toward higher-growth Med Tech offerings. Those platforms accounted for 49% of total revenue in the most recent quarter, up from 47% a year earlier. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors track the name for its Med Tech execution, the route to sustained profitability, and upcoming clinical and reimbursement developments in atherectomy, thrombectomy, and ablation.

ANGO Stock Performance Over the Past 30 Days and Quarter

ANGO declined about 26.8% in the last 30 days, moving from a September 8, 2026 close of $15.22 down to roughly $11.14 in early October. The drop came in a concentrated window after the fiscal first-quarter results and leadership announcement on October 8 rather than through steady erosion.

Looking back over the full quarter, the shares started the summer near $12.80, climbed to a 52-week high around $16.29 in late August, then gave back those gains and fell further in October. From what I see, ANGO finished the three-month stretch down roughly 13%, a figure that hides the earlier rally and subsequent reversal.

Factors Behind the Recent 30-Day Move in ANGO

The main driver was the fiscal 2027 first-quarter release on October 8, 2026, covering the period ended August 31. Revenue reached $80.9 million, a 6.9% year-over-year increase and ahead of the roughly $80.5 million consensus. Adjusted loss per share came in at $0.04, better than the expected $0.11 loss, while adjusted EBITDA rose to $5.0 million from $2.2 million.

Even with those beats, the stock fell more than 20% on the day. The company still recorded a GAAP net loss of $7.1 million, or $0.17 per share. Investors also factored in the CEO transition, with Eric Honroth, formerly a senior executive at Getinge, set to take over from Jim Clemmer on November 2, 2026. Gross margin expanded 410 basis points to 59.4%, helped by a $1.2 million tariff refund; without it the margin would have been near 57.8%. Management indicated tariff effects in fiscal 2027 should track those of fiscal 2026.

Quarterly Drivers and Market Reaction

Through July and August the shares advanced on steady Med Tech progress. Auryon posted its 21st straight quarter of double-digit growth, NanoKnife saw record procedure volumes in prostate applications, and mechanical thrombectomy continued to gain traction. The move to the 52-week high near $16.29 reflected optimism around that momentum and expanding reimbursement for NanoKnife. I reviewed the numbers with Tickeron’s AI Trend Prediction Engine to confirm the trends.

September brought consolidation back toward the $15 level, and the October earnings release triggered the sharper reversal. Across the three-month period the underlying Med Tech growth narrative stayed intact, even as attention turned to ongoing GAAP losses, the makeup of margins, and the upcoming leadership change.

Key Items to Monitor for ANGO Going Forward

Investors will focus on the November 2, 2026 CEO transition and any early signals on strategic direction under new leadership. Progress toward making Med Tech the majority of revenue in fiscal 2027, continued Auryon and NanoKnife expansion, and adoption of mechanical thrombectomy remain central themes. Clinical and reimbursement updates, including NanoKnife coverage expansion, the RELIEF study in benign prostatic hyperplasia, the AMBITION BTK study for Auryon, and the AlphaReturn and AngioVac IDE trials, will also matter. Tariff effects on margins and the target of positive operating cash flow for the full fiscal year round out the list of items worth watching.

Exploring AI-Powered Trading Tools

In my own analysis I sometimes reference Tickeron’s curated selection of AI trading bots to compare strategies across different timeframes and market conditions. The Trending AI Robots page highlights top-performing bots that monitor thousands of tickers, giving a practical view of which approaches are drawing attention right now. It serves as a neutral starting point when I want to see how data-driven signals align with the fundamentals I am reviewing.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ANGO

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ANGO's Indicator enters downward trend

The Aroon Indicator for ANGO entered a downward trend on October 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 161 similar instances where the Aroon Indicator formed such a pattern. In 134 of the 161 cases the stock moved lower. This puts the odds of a downward move at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANGO as a result. In 69 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.

ANGO moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ANGO crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ANGO's RSI Oscillator exited the oversold zone, 24 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for ANGO just turned positive on October 23, 2026. Looking at past instances where ANGO's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.

Following a +4.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANGO advanced for three days, in 197 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

ANGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.838) is normal, around the industry mean (4.964). P/E Ratio (-13.330) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.005) is also within normal values, averaging (56.876).

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. ANGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.78B. The market cap for tickers in the group ranges from 126 to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 4%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 16%. ZJYL experienced the highest price growth at 80%, while STVN experienced the biggest fall at -30%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 0%. For the same stocks of the Industry, the average monthly volume growth was 45% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 53
Price Growth Rating: 51
SMR Rating: 81
Profit Risk Rating: 93
Seasonality Score: 19 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of medical devices used by radiologists, vascular surgeons and other physicians

Industry PharmaceuticalsOther

Industry
Medical Specialties
Address
14 Plaza Drive
Phone
+1 518 795-1400
Employees
632
Web
https://www.angiodynamics.com
Interact to see
Advertisement
AtlasClear Holdings (ATCH) shares fell roughly 25.5% over the last 30 days, declining from $0.1881 on October 2 to $0.1401 on October 30. The pullback extended a longer downtrend that has kept the stock trading well below the $1.00 NYSE American minimum, keeping continued listing-compliance risk in focus.
NVDA dropped from Friday's close of $186.64 to $174.06 intraday, down -6.74%, during regular market hours. The slide followed CEO Jensen Huang's admission of an extramarital affair and the board's independent investigation, announced November 8, after reports he was targeted by a suspected Chinese intelligence operative.
CCAP climbed +7.03% during regular market hours, rising from a prior close of $9.24 to $9.89. The rally followed its Q3 2026 report: net investment income of $0.37/share beat the $0.35 consensus and revenue of $36.9M topped estimates, alongside a new $50M buyback authorization plus up to $25M in additional Sun Life purchases.
NVDA fell -2.10% to $216.66 during regular trading, down from a prior close of $221.30. Primary catalyst: hotter-than-expected September CPI data reignited Fed rate-hike fears, raising borrowing costs for AI infrastructure buildouts.
The central stock price target of $100 is the arithmetic mean of the verified analyst price targets reviewed; major aggregators report a similar consensus near $99–$102, with a wide range from roughly $60 to $150. With the stock trading near $53, reaching $100 would require a gain of approximately 88% — a very large move from current levels.